Highlights Crossject

Equities

ALCJ

FR0011716265

Market Closed - Euronext Paris Other stock markets 11:17:42 2024-04-30 am EDT			5-day change	1st Jan Change
2.05 ^EUR	-0.73%		-4.65%	-58.75%

Apr. 03	CROSSJECT : Patience is a virtue… hopefully	AL
Apr. 02	Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CROSSJECT : Patience is a virtue… hopefully	Apr. 03	AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
CROSSJECT : Invest Securities slightly reduces its target	Feb. 28	CF
CROSSJECT : Securing the financing needs	Feb. 28	AL
Crossject: share price falls after convertible bond issue	Feb. 27	CF
CROSSJECT : No news is not always good news...	Feb. 08	AL
Crossject: strategy advances, but visibility worries	Feb. 07	CF
CROSSJECT : Marketing initiative in the US	Jan. 06	AL
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment	Jan. 05	MT
CROSSJECT : A new distribution agreement in Northern Europe	Jan. 03	AL
Crossject: commercial agreement in Northern Europe	Dec. 22	CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe	Dec. 22	CI
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US	23-09-05	MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication	23-07-20	MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand	23-07-20	CI
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Crossject to Release Positive Headline Results of Its Clinical Study with Zeneo® Midazolam	22-11-02	CI
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-19	CI
Crossject Announces Agreement with Barda on Zeneo® Midazolam	22-06-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Crossject

Equities

ALCJ

FR0011716265

Highlights

Filters